Revolution Medicines (RVMD) Net Cash Flow (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Net Cash Flow of $57.2 million for Q1 2026, up 127.3% year-over-year from $25.2 million in Q1 2025, and down 65.61% quarter-over-quarter from $166.3 million in Q4 2025.
Revolution Medicines (RVMD) Net Cash Flow (2019 - 2026) Analysis & Trends
Revolution Medicines' Net Cash Flow history runs 8 years deep, the most recent figure standing at $57.2 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 127.3% year-over-year to $57.2 million; the TTM figure through Mar 2026 stood at $108.5 million (up 137.05% YoY), while the FY2025 annual figure was -$158.2 million, down 3.77% from the prior year.
- Net Cash Flow for Q1 2026 stood at $57.2 million, down from $166.3 million in the prior quarter.
- The five-year high for Net Cash Flow was $342.6 million in Q4 2024, with the low at -$407.7 million in Q1 2024.
- The 5-year median for Net Cash Flow is -$10.8 million (2022), against an average of $19.7 million.
- Peak annual rise in Net Cash Flow reached 2554.39% in 2023, while the deepest fall reached 667.35% in 2023.
- Revolution Medicines' Net Cash Flow stood at -$17.5 million in 2022, then soared by 2030.45% to $338.4 million in 2023, then gained by 1.25% to $342.6 million in 2024, then tumbled by 51.46% to $166.3 million in 2025, then sank by 65.61% to $57.2 million in 2026.
- Business Quant data shows RVMD's Net Cash Flow at $57.2 million in Q1 2026, $166.3 million in Q4 2025, and -$184.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -170.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 374.50 Mn |
| Jun 30, 2026 | 374.50 Mn |
| Mar 31, 2026 | 57.19 Mn |
| Mar 31, 2026 | 57.19 Mn |
| Dec 31, 2025 | 166.30 Mn |
| Dec 31, 2025 | 166.30 Mn |
| Sep 30, 2025 | -184.05 Mn |
| Sep 30, 2025 | -184.05 Mn |
| Jun 30, 2025 | 69.10 Mn |
| Jun 30, 2025 | 69.10 Mn |
| Mar 31, 2025 | -209.51 Mn |
| Mar 31, 2025 | -209.51 Mn |
| Dec 31, 2024 | 342.61 Mn |
| Dec 31, 2024 | 342.61 Mn |
| Sep 30, 2024 | -74.59 Mn |
| Sep 30, 2024 | -74.59 Mn |
| Jun 30, 2024 | -12.72 Mn |
| Jun 30, 2024 | -12.72 Mn |
| Mar 31, 2024 | -407.72 Mn |
| Mar 31, 2024 | -407.72 Mn |